For the year ending 2025-12-31, JAZZ made $4,267,586K in revenue. -$356,148K in net income. Net profit margin of -8.35%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenues | 4,267,586 | |||
| Cost of product sales (excluding amortization of acquired developed technologies) | 503,296 | |||
| Selling, general and administrative | 1,809,271 | |||
| Research and development | 782,736 | |||
| Intangible asset amortization | 654,661 | |||
| Acquired in-process research and development | 947,862 | |||
| Total operating expenses | 4,697,826 | |||
| Income (loss) from operations | -430,240 | |||
| Interest expense, net | -195,051 | |||
| Foreign exchange gain (loss) | -2,568 | |||
| Income (loss) before income tax benefit and equity in loss of investees | -627,859 | |||
| Income tax benefit | -272,443 | |||
| Equity in loss of investees | -732 | |||
| Net income (loss) | -356,148 | |||
| Basic EPS | -5.84 | |||
| Diluted EPS | -5.84 | |||
| Basic Average Shares | 60,981,000 | |||
| Diluted Average Shares | 60,981,000 | |||
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ)